Side-by-side comparison of AI visibility scores, market position, and capabilities
Kellanova acquired by Mars Inc. Aug 2024 for $35.9B ($83.50/share); Pringles, Cheez-It, Pop-Tarts, Eggo integrated into Mars global snacking alongside M&M's/Snickers competing with Frito-Lay and Mondelez.
Kellanova (formerly Kellogg Company's global snacking division) was a Chicago, Illinois-based snacking company — creator of Pringles (the world's second-largest potato chip brand), Pop-Tarts, Cheez-It, Rice Krispies Treats, MorningStar Farms plant-based foods, Eggo waffles, and Nutri-Grain cereal bars — that was created in August 2023 when Kellogg Company split into two independent public companies: Kellanova (global snacking brands, cereal outside North America) and WK Kellogg Co. (North American cereal brands). Kellanova was itself acquired by Mars, Incorporated in August 2024 in a $35.9 billion cash transaction ($83.50 per share) — one of the largest food industry acquisitions in history — ending Kellanova's brief 12-month existence as a standalone public company. Mars acquired Kellanova to expand its snacking portfolio (Mars's existing snacking brands include M&M's, Snickers, Twix, Kind bars, and Nature's Bakery) with Kellanova's salty snacks platform (Pringles, Cheez-It) and convenient breakfast products (Pop-Tarts, Eggo) — creating a combined snacking company with $35+ billion in revenue that competes directly with PepsiCo's Frito-Lay and Mondelez International's snacking portfolio. Prior to the Mars acquisition, Kellanova CEO Steve Cahillane had executed the strategic rationale for the split from WK Kellogg: snacking brands (impulse purchase, premium innovation, global growth) warranted a different capital allocation and growth investment profile than mature North American cereal brands (stable cash flow, distribution efficiency). Kellanova's FY2023 revenues totaled approximately $13 billion, with Pringles generating the highest brand-level profitability through its unique pressurized-air canister distribution system.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.